New cancer combo drug tested in tiny trial – is it safe?
NCT ID NCT06894771
First seen Sep 30, 2025 · Last updated May 08, 2026 · Updated 24 times
Summary
This early-phase study tested a new drug called MK-4700, given alone or with another cancer drug (pembrolizumab), in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to check safety and find a dose that people can tolerate. No conclusions about effectiveness can be drawn from this small safety study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0102)
Québec, Quebec, G1J 1Z4, Canada
-
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0301)
Hackensack, New Jersey, 07601, United States
-
NEXT Oncology ( Site 0300)
San Antonio, Texas, 78229, United States
-
Princess Margaret Cancer Center ( Site 0101)
Toronto, Ontario, M5G 2M9, Canada
-
Rabin Medical Center ( Site 0202)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus ( Site 0201)
Haifa, 3109601, Israel
-
Sheba Medical Center ( Site 0200)
Ramat Gan, 5265601, Israel
Conditions
Explore the condition pages connected to this study.